THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).

Trial Details

NCT ID
NCT07446257
Phase
EARLY_PHASE1
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ateganosine
  • Cadonilimab
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Diagnosis of HCC confirmed by histology or according to the American Association for the Study of Liver Disease (AASLD) criteria
  • a. Availability of tumor tissue samples prior to the first day of study treatment is required for all patients.
  • HCC that is amenable to R0 resection with curative intent as determined by treating surgical/medical oncologists in consultation with the principal…
  • Measurable disease according to RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →